Description

Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-protein/nucleotide metabolism–C126H199N36O38S3F3—-[1]Wei CM, et al. Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest. 1993;92(4):2048-2052.|[2]Chen BY, et al. Vasonatrin peptide, a new regulator of adiponectin and interleukin-6 production in adipocytes. J Endocrinol Invest. 2011;34(10):742-746.|[3]Shi Z, et al. Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms. Am J Physiol Heart Circ Physiol. 2015;308(4):H281-H290.—-2979.39–98.79–OC(C(F)(F)F)=O.OC1=CC=C(C[C@H](NC([C@@H](NC([C@H](CC2=CC=CC=C2)NC([C@@H](NC([C@@H](NC([C@@H]3CSSC[C@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC(CN)=O)CC(C)C)=O)CO)=O)CCCCN)=O)=O)C(N[C@@H](CC4=CC=CC=C4)C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@]([H])([C@H](CC)C)C(NCC(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CO)C(NCC(N[C@@H](CC(C)C)C(NCC(N3)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC(N)=O)=O)CO)=O)=O)CCCNC(N)=N)=O)C(O)=O)C=C1–Metabolic Disease–10 mM in DMSO–PKG—-Stem Cell/Wnt–Peptides